usual agil alway success execut growth strategi tp
maintain buy rate agil maintain
tp deriv tp ep
along earn multipl
estim top line growth
estim base follow factor strong
growth revenu improv oper margin strong
growth pharma chemic market
success execut strategi acquisit strengthen
portfolio
agil success execut agil agil strategi
deliv signific earn cash flow growth
gener oper cash flow paid
agil revenu increas
revenu growth impact lunar new year earli
demand product reduc
chemic market deliv growth
quarter academia govern grew
food revenu declin due chines govern
reorgan food safeti ministri
agil saw strong growth segment lsag segment
grew acg segment grew dcg segment
grew agil also see strong momentum
newli releas product deploy capit strengthen
portfolio
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
column acg segment target industri food
flavor fragranc market
agil acquir advanc analyt
add complementari biomolecul separ
capabl agil portfolio
agil also acquir genohm develop highli
differenti softwar solut sampl track
agil announc collabor biotek instrument
cellular metabol analysi imag technolog
agil seahors analyz
net incom increas
ep increas non-gaap ep
increas
agil expect revenu grow
expect revenu rang
expect ep
current price-to-earnings near averag price-to-earnings
rang
expect forward price-to-earnings multipl
expect agil grow
given buy rate stock base
perform acquisit made strengthen
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jul ex-dividend date jul last split factor new per last split date inform agil technolog inc| june
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non reconcili refer
incom statement item total gross research develop sell gener administr sg oper depreciation- oper profit interest incom special charges- interest incom minor incom incom net incom outstand dilut ep dilut ep dividend paid per share inc| june
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item agil inc| june
net cash inflow oper activ period compar
cash inflow net cash provid oper activ
compar
net cash use invest activ period compar
net cash use invest activ compar
net cash use financ activ period compar
net cash use financ activ compar
depreciation- defer incom taxes- oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc| june
agil deliv signific earn cash flow growth strong top-lin
result success execut growth strategi agil saw strength
pharma growth chemic market
growth agil chines custom request deliveri
earlier anticip pull revenu
due earli deliveri estim agil result impact
lunar new year number sell day reduc
agil revenu increas compar
revenu neg impact lunar new year due
fewer sell day lower shipment volum custom request
earlier deliveri result revenu recogn instead
net product revenu increas compar
servic revenu increas
compar
cog increas compar
gross margin flat compar reflect
higher sale volum lower amort expens off-set increas wage
variabl pay higher inventori charg unfavour currenc
 expens increas compar
expens increas due increas program spend new
product relat busi addit higher wage
variabl pay unfavor currenc movement
sg expens increas compar
increas due higher wage variabl pay higher
sell cost transform initi cost partial off-set lower share-
increas
neg
impact lunar
new year due
sell day lower
gross margin
flat
compar
off-set increas
wage variabl pay
unfavour
oper margin rel flat compar
impact lower acquisit integr cost lower
amort expens off-set increas wage variabl pay cost
sg cost unfavor currenc movement
effect tax rate fell compar
incom tax expens
net incom increas compar
agil intang amort busi exit
divestitur transform initi acquisit
integr cost net gain exclud item
tax benefit agil report non-gaap net incom
ep increas compar
non-gaap ep increas
agil gener oper cash flow paid
dividend repurchas share
gaap ep increas
compar
non-gaap
ep increas
net revenu
compar
net revenu period increas compar
foreign currenc movement favor impact
revenu ppt compar prior year period
net product revenu period increas
compar servic revenu
period increas compar
cog increas period compar
gross margin period increas ppt
compar increas due higher sale volum
favor busi mix lower manufactur materi cost lower
amort expens intang asset partial off-set increas wage
variabl pay inventori charg
 expens period increas
compar expens increas due increas program
spend new product relat busi addit higher
wage variabl pay unfavor currenc movement
oper margin
period
rel flat
compar
sg expens period increas
compar increas expens due higher wage
variabl pay increas corpor cost higher share-bas compens
expens higher sell administr cost unfavor currenc
oper margin period rel flat
compar impact lower acquisit integr
cost lower amort expens
effect tax rate period increas
compar incom tax expens
period effect tax rate result provis
incom tax significantli impact discret charg
relat enact tax job act
net loss period compar net incom
due increas tax rate ep period
compar
net loss
period
compar net
incom
due increas
tax rate ep
period
compar
revenu major
total revenu
dx clinic market
contribut total
revenu
revenu geographi
 contribut total revenu
europ contribut total revenu
asia pacif region contribut total revenu
revenu type instrument revenu quarter contribut total
revenu consum servic informat contribut total revenu
revenu major market analyt laboratori contribut total
revenu dx clinic market contribut total revenu
revenu segment lsag contribut total revenu acg contribut
total revenu dgg contribut total revenu
result revenu end-market
agil strong growth quarter due gain pharma
agil strong
growth
quarter due gain
pharma chemic
diagnost clinic
grew y/i core
basi led strength
reagent
partnership
off-set continu
weak
y/i core basi
pharma led strength mass spectrometri consum
servic across small molecul bio-pharma
academia government due increas demand mass spectrometri
cell analysi crosslab
environment forens due strong gain global forens
food china food safeti reorgan result temporari
slow new instrument
chemic in-lin expect difficult
diagnost clinic end market revenu grew y/i core basi led
strength reagent partnership genom busi off-set
continu weak pain manag market
chemic energyfoodenviron forensicdx clinicalacademia governmentpharma biotech agil inc| june
life scienc appli market group lsag
life scienc appli market busi provid application-focus solut
includ instrument softwar enabl custom identifi
quantifi analyz physic biolog properti substanc
product well enabl custom clinic life scienc research
area interrog sampl molecular cellular level
compar
lsag revenu increas compar
total revenu period increas y/i
compar foreign currenc movement
overal favor impact revenu ppt period
month period
technolog
capabl agil
pharmaceut biotechnolog market strong revenu
growth life scienc research market within appli market
strong revenu growth chemic energi market modest
growth environment forens market
month period revenu growth partial off-set
declin food market revenu relat food market
contribut revenu growth period
lsag incom oper compar
incom oper period
compar oper margin increas
bp compar prior year period
agil acquir advanc analyt add
complementari biomolecul separ capabl agil portfolio
agil also acquir genohm develop highli differenti softwar
solut sampl track lab manag
agil announc collabor biotek instrument cellular
metabol analysi imag technolog expand real time cell
activ measur capabl agil seahors analyz
agil crosslab busi span entir lab extens consum
servic portfolio design improv custom outcom
product categori consum includ gc lc column sampl
prepar product custom chemistri larg select laboratori
instrument suppli servic includ start-up oper train
complianc support softwar servic well asset manag
consult servic help increas custom product
agil crosslab group revenu increas
compar total revenu period
increas compar
foreign currenc movement overal favor impact revenu
ppt ppt period revenu grew across
nearli key market led strong growth pharmaceut
biotechnolog market life scienc research market primarili driven
consum portfolio china deliv double-digit growth
major geographi grew mid high-singl digit
revenu increas
compar
column target
industri food
flavor fragranc
acg incom oper increas compar
incom oper period
compar oper margin increas
bp compar prior year period
agil launch innov high temperatur wax gc column target
industri food flavor fragranc market
agil expand agil enabl servic acceler
custom time-to-valu purchas includ addit instrument
agil open new global solut develop center singapor
meet increas demand integr end-to-end solut
diagnost genom group dgg
diagnost genom busi includ genom nucleic acid contract
manufactur patholog companion diagnost reagent
partnership busi compris five area activ provid solut
includ reagent instrument softwar consum enabl
custom clinic life scienc research area interrog sampl
cellular molecular level
dcg revenu increas compar
total revenu period increas
compar
foreign currenc movement period
overal favor impact revenu ppt compar
period last year revenu growth strong
pharmaceut market diagnost clinic market led
reagent partnership genom busi
dcg incom oper compar
incom oper period
compar oper margin decreas bp
compar prior year period
agil expand situ hybrid probe portfolio dako omni
releas proprietari color immunohistochemistri stain
help pathologist assess skin lung tissu
agil acquir outstand share lasergen bring agil
power sequenc chemistri world-class group scientist
engin dedic introduc integr clinic workflow solut
molecular diagnost
compar
agil expand
probe portfolio
proprietari color
stain
assess skin lung
agil recent action profit growth plan includ
deliv agil agil initi
multi-year program increas effici custom focu
oper margin continu expand adjust fx
portfolio invest go-to-market capabl
biomolecul separ capabl agil capillari electrophoresi
acquir genohm develop highli differenti softwar solut
sampl track lab manag
acquir outstand share lasergen bring agil
power sequenc chemistri world-class group scientist
engin dedic introduc integr clinic workflow solut
molecular diagnost
continu expand on-lin capabl readi use cart featur
on-line store gener new custom web registr increas
order
announc collabor biotek instrument cellular metabol
analysi imag technolog expand real time cell activ
measur capabl agil seahors analyz
expand situ hybrid probe portfolio dako omni
releas proprietari color immunohistochemistri stain
help pathologist assess skin lung tissu
agil acquir
outstand share
lasergen bring
world-class group
scientist
engin dedic
introduc
workflow solut
guidanc mid point
revenu expect
grow
ep expect
revenu growth mid-point core growth
oper margin mid-point adjust
keysight bill classifi incom
revenu expect
rang
revenu growth mid-point core growth
agil saw strong growth revenu due growth pharma
chemic market grew quarter deliv
signific increas earn cash flow gener oper cash
flow paid dividend
agil revenu increas agil saw strong
growth segment lsag segment grew acg segment grew
dcg segment grew
innov front agil launch new product deploy
capit acquisit strengthen portfolio agil launch innov
high temperatur wax gc column acg segment target industri
food flavor fragranc market agil acquir advanc analyt
technolog add complementari biomolecul separ capabl
agil portfolio agil also complet acquisit genohm
lasergen inc add new strateg capabl drive futur growth
agil announc collabor biotek instrument cellular metabol
analysi imag technolog expand real time cell activ
measur capabl agil seahors analyz
gaap ep increas non-gaap ep increas
ytd stock perform agil compar
 roa ttm agil compar
industri averag roe ttm agil compar
growth revenu
due growth pharma
chemic
market grew
quarter
agil launch
new product
deploy capit
acquisit
strengthen portfolio
non- reconcili
non- reconcili
non- reconcili
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin flat ttm basi compar
revenu growth increas ttm basi compar
net margin reduc ttm basi compar due increas tax
ep growth reduc ttm basi compar
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale agil inc| june
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqreturn mrqcapex salescap ex salesfre mrqreturn equiti agil technolog inc| june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item agil technolog inc| june
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free inc| june
current price-to-earnings closer averag price-to-earnings rang
price-to-earnings averag price-to-earnings around
expect forward price-to-earnings multipl
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form michael paul boon institut holdersholdershar report outvaluepric row associ vanguard group inc fmr jp morgan state mutual automobil insur primecap manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market price row mid cap growth vanguard spdr etf price row vanguard institut fund-institut price row valu ishar vanguard growth fidel inc| june
developmentsagil expand portfolio probe situ hybrid inc announc releas rang new probe forin situhybrid techniqu use patholog laboratori obtain inform gene express new probe address need cleanli accur interpret data fluoresc situ hybrid fish chromogen situ hybrid cish complet acquisit advanc analyt inc inc announc complet acquisit advanc analyt inc aati provid capillari electrophoresis-bas ce solut fully-autom analysi rang molecul cash acquisit bring togeth two innov electrophoresi space aati develop compel product base ce technolog provid key advanc sensit resolut address wide rang applic across varieti industri segment agil open global solut develop center singapor inc open new facil singapor dedic develop integr end-to-end workflow across rang disciplin includ pharma biopharma lipidom food test agil creat new global solut develop center meet increas demand fulli test solut aim center optim laboratori process introduc transform way boost product agil biotek join forc creat integr metabol analysi imag platform inc andbiotek instrument inc announc new integr solut combin cellular metabol analysi imag technolog optim solut integr agil seahors analyz biotek cytat cell imag multi-mod reader solut creat standard approach compar xf data set improv assay workflow embed imag wave softwar appli normal valu seahors xf measur june inc| june
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
agil
compar
sale growth
ttm compar
industri averag
roa ttm
agil compar
industri averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit agil inc| june
consensu view analyst trend stock
forecast agil
compar
average
forward price-to-earnings
compar
 avgfive-year growth forecast usdgrowth high day day day estim comparisonaindustri avg avgprice/earn yield inc| june
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate agil technolog inc| june
price target summarycrispidea suissedowngradeneutralund robinson co downgrademarket performrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext agil inc| june
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price movement show huge fluctuat quarter dip
result announc volum share trade increas day
averag volum trade quarter stock gave neg return
stock volatil year gave return last one year
stock high low
stock price show uptrend last three year gave return last three year
stock gave good return last three year due consecut increas oper margin
strong perform
agil deliv strong result due growth pharma chemic energi market agil
complet acquisit strengthen portfolio success execut strategi gave agil
buy rate base perform product portfolio maintain tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
